27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a lawsuit that will surely be followed closely by the cannabis investment community, the American Civil Liberties Union (ACLU) of Nevada is suing to remove cannabis schedule 1 designation from the state Nevada State Board of Pharmacy's list of Schedule I drugs. If successful, the decision court set an interesting precedent at the state court level.
Pictured is the first page of the lawsuit. Going to be following this case closely to see if a precedent is established in the state courts. If it goes there, we may have something to get excited about. $MSOS pic.twitter.com/PCfdxPHuTh
— The Dales Report (@TheDalesReport) April 19, 2022
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Plaintiffs—Cannabis Equity and Inclusion Community (CEIC), Antoine Poole and through counsel of the ACLU—are seeking injunctive relief (NRS Chapter 33). Specifically, the Plaintiffs are seeking an order directing the Nevada State Board of Pharmacy to remove cannabis and cannabis derivatives from NAC 453.510 as Schedule I substances, as well as reasonable costs in attorney's fees pursuant to NRS 18.010.
NAC 453.510 is the Nevada Legislature Schedules Of Controlled Substances and similar to the "orange book" of controlled substances cited by the United States Department of Justice. The NRS 18.010 is a statute allowing a “prevailing party” to recover attorney fees and costs in certain circumstances.
The lawsuit alleges that despite the passage of the Nevada Medical Marijuana Act and the Initiative to Regulate and Tax Marijuana, the state—specifically Nevada State Board of Pharmacy—has failed to comport with the will of Nevada voters, the state Constitution and revised statutes. Instead of removing cannabis and cannabis derivatives from its list of controlled substances (NAC 453.510), the Board has continued to regulate them as Schedule 1 substances—similar to that of hardcore drugs, such as methamphetamins and heroin, with no medicinal benefit.
Thus, the failure to amend NAC 453.510 is a constitutional and statutory violation that can only be remedied by removing cannabis and cannabis derivatives from the list of official Schedule 1 drugs.
In 2000, Nevada voters ratified an amendment to the Nevada Constitution to legalize marijuana for medical use. While in 2016, Nevadans voted to legalize cannabis for recreational use. Cannabis Schedule 1 designation remains in lockstep with the federal designation of cannabis.
This article was originally published on The Dales Report and appears here with permission.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.